Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 73Colonic Neoplasms 14Rectal Neoplasms 13Neoplasm Metastasis 12Stomach Neoplasms 8Pancreatic Neoplasms 5Advanced Solid Tumors 5Neoplasms 4Colorectal Cancer Metastatic 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Gallbladder Neoplasms 3Cholangiocarcinoma 3Carcinoma 3Adenocarcinoma 3Neutropenia 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Biliary Tract Neoplasms 2Bile Duct Neoplasms 2Advanced Solid Tumors (Excluding Breast Cancer) 2Advanced Colorectal Cancer 2Adenocarcinoma Of Esophagus 2mCRC 1Urologic Diseases 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Spinocerebellar Degenerations 1Solid Tumor Cancer 1Solid Tumor 1

Interventions

Cetuximab 2Bevacizumab 2trifluridine tipiracil drug combination 1S 1 (combination) 1Oxaliplatin 1Leucovorin 1Irinotecan 1Fluorouracil 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
mCRC × trifluridine tipiracil drug combination × Clear all
NCT07116577 2025-08-11

Radiotherapy Combined QL1706, TAS-102 and Bevacizumab in mCRC

Jinan Central Hospital

Phase 2 Not yet recruiting
37 enrolled

mCRC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡